Skip to main content
Premium Trial:

Request an Annual Quote

DNA Software Nets $2.5M in SBIR Funds

NEW YORK (GenomeWeb News) – DNA Software has won three grants totaling $2.5 million from the National Institutes of Health to support the development of its software for use in predicting the structure of bacterial ribosomes and modeling the reaction rates of DNA and RNA experiments.

In one of the grants, the company will use the Phase II Small Business Innovation Research funding to support development of its Nucleic Acid CAD software, which predicts the 3D structures of clinically relevant pathogens.

Half of the antibiotics currently on the market target bacterial ribosomes, but the 3D structures of many of these RNA complexes are still unknown, the Ann Arbor, Mich.-based bioinformatics company said in a statement, adding that knowledge about ribosome structure is critical for the development of new antibiotics for drug-resistant bacteria.

In another project, DNA Software is adding information about kinetics and modified nucleotides to its existing Oligonucleotide Modeling Platform software with the aim of using it to develop selective diagnostics.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.